EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Cardiovascular Risk in Psoriatic Arthritis: Mechanisms, Risk Assessment, and Long-Term Management Implications

Stefan Totolici, Ana-Maria Vrabie, Catalin Adrian Buzea iD, Elisabeta Badila iD

International Journal of Molecular Sciences · 09.05.2026 · 27 (10) · 4226

DOI: 10.3390/ijms27104226 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 09.05.2026. Verfasst von Stefan Totolici und 3 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Department, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania. Hauptthemen laut MEDLINE: Heart Disease Risk Factors, Arthritis, Psoriatic, Cardiovascular Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Beyond its typical synovio-entheseal manifestations, psoriatic arthritis (PsA) is a systemic immune-mediated disease that carries a substantial, independent risk of major adverse cardiovascular events (MACE). The complex interaction of chronic systemic inflammation, a high prevalence of traditional risk factors, and PsA treatment drugs results in this increased cardiovascular burden, which is commonly underestimated in cardiology practice. Adipokine balance, insulin signalling, and lipid metabolism are all impacted by cytokine-driven systemic inflammation, which promotes metabolic abnormalities and accelerated atherogenesis. PsA-specific therapy has a complex and significant effect on cardiovascular risk. While there is evidence that strong inflammation suppression with tumour necrosis factor-α (TNF-α) inhibitors may reduce cardiovascular risk, some medications, such as Janus kinase (JAK) inhibitors, should be carefully considered due to potential side effects. In order to outline the epidemiology and pathophysiology of the PsA-cardiovascular risk nexus, this narrative review synthesises recent data. It also offers a critical framework for managing cardiovascular risk in this susceptible group, advocating for a multidisciplinary approach that incorporates strict management of both inflammation and traditional risk factors to lessen the excessive burden of MACE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart Disease Risk FactorsArthritis, PsoriaticCardiovascular DiseasesHumansRisk Assessment

Stichwörter der Autor:innen

atherosclerosiscardio-rheumatologycardiovascular diseasecardiovascular riskmajor adverse cardiovascular eventspsoriatic arthritissystemic inflammation

Autor:innen und Institutionen

  • Cardiology Department, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.
  • Colentina Clinical Hospital, 020125 Bucharest, Romania.

ORCID-Profile: Catalin Adrian Buzea, Elisabeta Badila

Zitieren

APA

Totolici, S., Vrabie, A. M., Buzea, C. A., & Badila, E. (2026). Cardiovascular Risk in Psoriatic Arthritis: Mechanisms, Risk Assessment, and Long-Term Management Implications. International Journal of Molecular Sciences, 27(10), 4226. https://doi.org/10.3390/ijms27104226

Vancouver

Totolici S, Vrabie AM, Buzea CA, Badila E. Cardiovascular Risk in Psoriatic Arthritis: Mechanisms, Risk Assessment, and Long-Term Management Implications. International Journal of Molecular Sciences. 2026;27(10):4226. doi:10.3390/ijms27104226

BibTeX
@article{Totolici2026,
  author = {Totolici, Stefan and Vrabie, Ana-Maria and Buzea, Catalin Adrian and Badila, Elisabeta},
  title = {Cardiovascular Risk in Psoriatic Arthritis: Mechanisms, Risk Assessment, and Long-Term Management Implications},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {10},
  pages = {4226},
  doi = {10.3390/ijms27104226}
}
Kostenlos starten →